anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mania is a serious condition characterized by extreme excitement, mental and physical hyperactivity, insomnia, and disconnected thoughts. Symptoms of mania are common in patients with schizophrenia or bipolar disorder. When associated with these conditions, mania reaches psychotic proportions and often includes hallucinations, paranoia, and feelings of omnipotence. Such symptoms may put individuals with mania and those around them at risk for physical harm. Drug therapies that can safely and effectively treat symptoms of mania are needed. This study will compare three drug combinations in their ability to treat symptoms of mania in people with schizophrenia or bipolar I disorder.

This study will comprise a 12-week acute phase and a 14-week continuation phase. While the acute phase is the primary component of this study, the continuation phase will provide extended data on the characteristics and course of responders to the initial treatment combinations. Results from the continuation phase will be reported elsewhere. In the acute phase, participants will be randomly assigned to receive one of three treatments: divalproex-extended release (DV-ER) and lithium, DV-ER and quetiapine, or DV-ER and placebo. Participants will receive their intervention for 12 weeks. Participants will have weekly study visits for the first 4 weeks of the acute phase; biweekly study visits will occur for the following 8 weeks. After the acute phase, participants who have not responded to their drug regimen will complete their participation in the study.

Participants whose symptoms of mania have decreased will be offered enrollment in the 14-week continuation phase, during which time participants will continue the drug regimen they began in the acute phase. Participants will have biweekly study visits in the continuation phase. During each study visit in both phases, participants will be interviewed about their mania symptoms. Mania, depression, quality of life, and overall functioning scales will assess participants at study entry, at the end of the acute phase, and at the end of the continuation phase. Participants over 50 years of age will have an electrocardiogram (EKG) at study entry to determine cardiac function.
PURPOSE:The titled base having extremely increased time for adhesion to the oral cavity of the base for oral cavity drug, and improved feeling in use, containing a specific amount of pectin having specific particle size. CONSTITUTION:A base for oral cavity drug containing 5-60wt% pectin having >=150 meshes particle size as a binder, 3-90wt% ointment base such as vaseline, plastic base, etc. and 5-10wt% viscosity builder such as polyvinyl alcohol, etc. The pectin preferably has about 20wt% fine particles having about 200 meshes obtained by high-speed crushing. The base is mixed with extract of Lithospermi Radix, to give a drug for stomatitis. It is blended with tairase, to give a remedy for pyorrhea alveolaris, periodontitis, etc.
The utility model discloses a gynae external use Chinese traditional medicine bellyband, which is characterized in that the gynae external use Chinese traditional medicine bellyband is a double-layer band, the middle of which is wide and the two ends are narrow; the middle part of the band is provided with an opening, and a Chinese traditional medicine bag is arranged in the band from the opening and is filled with Chinese medicine mixture formed by artemisia leaf, hawkthorn, angelica, frankincense, myrrh, rhizoma corydalis, safflower and angelica. The Chinese traditional medicine bag in the bellyband of the utility model mainly cures irregular menstruation, dysmenorrheal, uterine bleeding and fetal irritability, etc. of women. The bellyband is attached on the cv8 acupuncture point part for a longer time, the medicine is absorbed through the skin of the cv8 acupuncture point and other ventral acupuncture points, and the bellyband directly plays blood promoting, channel freeing, phlegm eliminating and hemagogic actions for the ventral organs of the women, thereby playing complete action for the irregular menstruation, dysmenorrheal, uterine bleeding and fetal irritability, etc. of women. The gynae external use Chinese traditional medicine bellyband has convenient use and beautiful appearance without any side effect, and adult women in various ages all accept with pleasure.
The objective of this review is to summarize pertinent literature looking at family dynamics and/or adherence to treatment in pediatric functional constipation. A structured systematic literature search was conducted on MEDLINE, Embase, and Web of Science core collection libraries from the years 2000 to 2023 using specific search terms: constipation, treatment adherence, family dynamics, parenting style, and pediatrics. Seventy-one publications were identified and included for review. After screening based on alignment to the review, 20 publications remained. These publications were placed into three categories depending on their intent and findings: (1) recommendations to further increase adherence, (2) studies analyzing factors of adherence, and (3) studies stating a need for a better understanding of family factors. A future area of research is identifying the associations between family factors on adherence to constipation treatment regimens. Results from such studies would increase the amount of positive treatment outcomes and decrease unnecessary healthcare costs.
A process for the preparation of penicillanic acid 1,1-dioxide and esters thereof readily hydrolyzable in vivo. Said process involves dehalogenation of a 6-halo or 6,6-dihalo derivative of penicillanic acid 1,1-dioxide or ester thereof readily hydrolyzable in vivo or a carboxy protected derivative thereof (e.g. by hydrogenolysis). The 6-halo and 6,6-dihalo derivatives of penicillanic acid 1,1-dioxides, esters thereof readily hydrolyzable in vivo, and carboxy protected derivatives thereof are novel intermediates. Penicillanic acid 1,1-dioxide, and esters thereof readily hydrolyzable in vivo, are known compounds which are useful as beta- lactamase inhibitors and for enhancing the effectiveness of certain beta-lactam antibiotics (e.g. the penicillins) in the treatment of bacterial infections in mammals, particularly humans.
The present invention is adapted to provide real health-care decision analysis, risk analysis, and option analytics to individual participants, the need for which has arisen from the passage of the Affordable Care Act. The system and process simulate, optimize and visualize individual health plan options. The optimization utility uses the carrier component pricing, actuarial value calculations and phantom rate development as the basis of valuation for each of the medical and pharmacy benefit plan design permutations. Employer sponsored insurance funding, legislated premium tax credits and cost sharing reductions and individual account based funding are all factored into the process. A detailed preference analytics algorithm is used to formulate the appropriate individual risk profile in order to map the options. The individual has the ability to simulate customized scenarios as part of the tier paths defined in the Affordable Care Act.
This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
OBJECTIVE: Adults with rheumatic disease (RD) experience high levels of fatigue. Regular physical activity has been shown to reduce fatigue among adults. Despite this evidence, adults with RD are more likely to be physically inactive compared with those without RD. Little information is known about the association of physical activity level and fatigue among adults with RD. This study investigated the association of physical activity level and fatigue among adults with and without RD.
METHODS: Adults (≥18 y) who participated in the 2018 National Health Interview Survey (unweighted n = 25,471) were included in this cross-sectional study. Physical activity and fatigue were self-reported. Statistical analyses were weighted to account for complex survey sampling design.
RESULTS: Significantly more adults with RD experience fatigue compared with adults without RD (26.19% vs 13.23%). Adults with RD who were inactive had 2.81 times (95% CI, 2.37-3.34) higher odds of experiencing fatigue compared to adults with RD who were sufficiently active, after adjusting for covariates.
CONCLUSIONS: Overall, fatigue was more common among adults with RD than it was in the population without RD.
The objective of the CorEvitas Multiple Sclerosis (MS) Registry is to create a national cohort of patients with MS. Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of MS. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the prevalence and incidence of comorbidities and adverse events, medication utilization patterns and patient productivity measures.

The design is a prospective, non-interventional, observational registry for patients with MS under the care of a licensed neurologist. Longitudinal follow-up data is collected from both patients and their treating neurologist (also known as "Providers" for a CorEvitas registry study) every 6 months (+/- 30 days) during routine clinical encounters using CorEvitas registry forms. These forms collect data on patient demographics, disease duration, medical history (including all prior and current treatments for MS), smoking status, alcohol use, disease activity and severity, pain, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes. After the enrollment visit, MS patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. The goal is to collect data from patients and providers at six month intervals. Adverse events may be volunteered spontaneously by the subject, or be discovered as a result of general questioning by the Investigator. During all CorEvitas related visits with the Investigator, subjects will be questioned regarding the occurrence of adverse events.
Fertility is known to decline significantly in women after the age of 35 years, and fecundity is almost completely lost after the age of 45 . As age increases the natural fecundity and pregnancy rates after assisted reproduction decrease .This reduction in fecundity is thought to be due to ovarian aging mainly, which is defined as a decline in both the quantity and quality of the ovarian follicle pool .The increase in patient's age is associated with poor ovarian response, as represented by smaller ovarian volume, lower antral follicle count and poor stromal vascularity. In addition to the reduction in fecundity, there is an increase in spontaneous abortion rates in this group of women .It has been reported that about 19% of all women undergo ART are 40 years, and they could be considered as expected poor responders .Various protocols of ovarian stimulation have been proposed to optimize IVF results in this age group, however, satisfactory results remain a challenge . The lack of initial central down-regulation in early follicular phase and adequate prevention of premature luteinizing hormone (LH) surge in late follicular phase provide GnRH antagonist protocol as a potentially proper option .The use of aromatase inhibitors in a GnRH antagonist protocol was suggested by some studies \[Mit. Yarali and colleagues demonstrated that adjuvant therapy with letrozole could improve the response \[Yarali et al., 2009\]. Meanwhile, in another study, adding letrozole to ovarian stimulation has no positive effect on the likelihood of pregnancy . Letrozole is a selective, non-steroidal third generation aromatase inhibitor. Letrozole causes a reduction in conversion of androstenedione and testosterone to estrone and estradiol by inhibiting the aromatase enzyme activity . According to some published studies, the decline in early follicular phase estrogen levels, and consequently decrease in negative feedback of estrogen on FSH release in hypothalamic-pituitary axis cause an increase in endogenous gonadotropin secretion and stimulation of ovarian follicular growth. In addition, an increase in intraovarian androgens secondary to aromatase inhibition, augments the follicular sensitivity to FSH stimulation and follicular growth . Letrozole has no antiestrogenic effect over the endometrium . These reports prompted us to hypothesize that use of letrozole as a co-treatment agent in GnRH antagonist protocol might enhance cycle outcomes.

I
The present invention relates to a novel prodrug of aldo-keto reductase inhibitor II based on its disulfide (system name "disulfane") of formula I, to a process of the preparation of disulfide of formula I, to the use of disulfide of formula I to inhibit the aldo-keto reductases AKR1B1 and AKR1B10, to the use of disulfide of formula I in the prevention or treatment of diseases in which the activity of the aldo-keto reductases AKR1B1 and AKR1B10 is a key etiological factor for their formation and development, the use of disulfide of formula I for the prevention or treatment of cancer originating from chronic inflammation, namely cancer of colon, lung, breast, liver, prostate, pancreas, endometrial and cervix. The invention also relates to the use of disulfide of formula I for the treatment of cancer as an adjuvant therapeutic in combination with clinically used chemotherapeutics, which may also be a substrate for aldo-keto reductases such as doxorubicin and daunorubicin. Disulfide of formula I itself is inactive as an inhibitor of aldo-keto reductases AKR1B1 and AKR1B10, but after oral or parenteral administration it is metabolized in the body, preferably in cancer cells characterized by increased reduction potential due to GSH content markedly increased compared to healthy cells, producing two molecules of cemtirestat of formula II the active inhibitor of aldo-keto reductase. The disulfide of formula I according to the invention may also have the advantage that it is better absorbed in the acidic environment of the tumors than cemtirestat of formula II alone. Disulfide of formula I can be used alone or in the form of pharmaceutically acceptable forms: a mono- or dibasic salt, mono- or diesters, amides, or combinations thereof or other pharmaceutical agents, optionally in combination with other anti-inflammatory or anti- cancer therapeutics. (I)
The present invention relates to a medicine composition for curing acne and scabies, which contains 30-60% of red powder (weight percentage, the same below), 20-40% of calomel and 20-35% of glauber salt, and its optimum proportion is equal to the above-mentioned three components. When in use, the ointment is mixed with sesame oil into paste to be applied to an affected part for 2 to 3 times a day, and the ointment is self-healed after 7 to 15 days. It can also be mixed with vaseline and glycerol to make into cream. The medicine integrates beauty treatment and treatment, treats acne and scabies with special effect, and has the curative effect of more than 95 percent. It can also be used for treating various dermatoses such as eczema, tinea, spider sore, and herpes zoster. Has repairing effect on scar after burn, scald and trauma, whitening skin, and no toxic and side effects, and can be eradicated once without recurrence.
A variety of clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B), an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of high density lipoprotein cholesterol (HDL-C) and its transport complex, apolipoprotein A (apo AI and apo AII) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and triglycerides, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined.  
  
Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apo AI and apo AII).  
  
The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPARα also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-cholesterol.  
  
Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.
PURPOSE:To provide a liquid antioxidant consisting of a specified unsatd. fatty acid triglyceride, natural antioxidant component derived from rosemary and/or sage and alcohol and exhibiting excellent lipid solubility and stability and forming no insolubies with time. CONSTITUTION:Natural antioxidant component (A) is prepared by extracting antioxidant ingredients of rosemary and/or sage by the use of an organic solvent (e.g. ethanol), followed by decoloring, deodorizing and if necessary removal of the organic solvent. The liquid antioxidant is prepared by dissolving 1pt.wt. by solid (A) in 1-100pts.wt. one or more of 6-12C unsatd. fatty acid triglyceride (e.g. capric acid) to which one or more alcohols (e.g. ethanol) is added when necessary. The liquid antioxidant is added to oil or fat or foods containing them in an amount of 0.001-5wt% of oil or fat.
<P>PROBLEM TO BE SOLVED: To obtain a gel-like bleaching material composition for teeth causing neither sticking to a spatula or vessel nor cobwebbing as a conventional problem in the operability for such bleaching materials, good in the adhesion to teeth surfaces and causing no spills from a tray.  <P>SOLUTION: This gel-like bleaching material composition for teeth comprises 60-90 pts. wt. of a polyhydric alcohol as the main solvent, 0.5-15 pt(s). wt. of a methyl vinyl ether/maleic anhydride copolymer as the thickening agent and 1-25 pt(s). wt. of urea peroxide as the bleaching component. In this composition, the methyl vinyl ether/maleic anhydride copolymer to be used is neutralized within pH5-7 in an anhydrous condition, and it is preferable that the copolymer is crosslinked with 1,9-decadiene and accounts for ≥20 wt.% of the thickening agent formulated in this composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The investigators have developed a tethered capsule OCT device intended as an inexpensive screening tool for BE. The capsule, which is attached to a thin, flexible tether, is reusable after being processed by a standard disinfection technique. Used without sedation, the capsule is swallowed by the participant and travels in the esophagus to the gastroesophageal junction (GEJ) via peristalsis. Cross-sectional microscopic OCT images of the entire esophagus are collected during transit. The total time needed for swallowing, imaging and retrieval does not exceed 10 minutes, with a total of 30 minutes for the procedure. The investigators have tested the feasibility and the tolerability of this new OCT screening technology in 250 procedures in healthy volunteers and patients with various esophageal diseases including BE. The procedure has been safe and well tolerated. High quality microscopic images of the esophagus have been obtained in 90% of the enrolled subjects.
Neonatal mortality continues to be unacceptably high in Kenya and other Sub-Saharan African countries, with little improvement over the past several decades. Neonatal infections and sepsis are a leading cause of neonatal deaths. Three fourths of these deaths occur in the first week of life. Many deliveries in rural Kenya take place at home in unhygienic conditions and the umbilical cord is cut with unsterile instruments, increasing the risk of infection. Studies in several countries with a high neonatal mortality rate have found a reduction in infection and mortality when chlorhexidine is applied to the umbilical cord stump by a health worker within 24 hours of birth. This randomized noninferiority study in rural Kenya will compare the effectiveness of a newborn home visitation program that includes application of chlorhexidine to the umbilical cord by a visiting community health worker (CHW) to the provision of chlorhexidine to the mother during a prenatal care visit for cord application on the rate of omphalitis (infection of the umbilical cord stump) during the first week of life. Pregnant women will be randomly assigned in a 1:1 ration to be given or not be given chlorhexidine digluconate 7.1% gel during a prenatal care visit with instruction to apply the product as soon as possible after birth. The pregnant women who do not receive the chlorhexidine will be assigned a CHW with instruction to apply the product during a home visit within 24 hours of birth. The rate of omphalitis will be determined during home visits by the CHW on days three and seven after birth, and by a visiting research nurse on the seventh day. The time from birth to chlorhexidine application will also be recorded and compared in the two groups.
FIELD: biotechnology, veterinary science, microbiology. SUBSTANCE: invention relates to production of vaccine preparations against pyocyanic infection in fur wild animals, mainly in polar fox and fox. Strain of bacterium Pseudomonas aeruginosa 524 1  is deposited in collection of strain-pathogens of sicknesses in fur wild animals of museum of bacterial and viral cultures of NII of fur farming and rabbit farming at number 524 1 . Strain is referred to serovariant 04. Strain is cultured in Marten's broth or synthetic media at 32 C for 18-20 h at constant shaking. After control of grown culture for toxicogenicity and proteolytic activity bacterial mass is separated and inactivated. Then aluminium hydroxide as an adjuvant is added and packaged. Invention ensures to prevent concealed loss in multiplication of fur wild animals in farm with pyocyanic infection being independently of pathogen pattern. EFFECT: strain indicated above, enhanced effectiveness of vaccine, improved method of preparing. 3 ex